{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T21:38:29Z","timestamp":1792791509626,"version":"4.5.0"},"reference-count":113,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T00:00:00Z","timestamp":1776297600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T00:00:00Z","timestamp":1776297600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Dis Primers"],"DOI":"10.1038\/s41572-026-00695-w","type":"journal-article","created":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T07:01:20Z","timestamp":1776322880000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["VEXAS syndrome"],"prefix":"10.1038","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5884-6231","authenticated-orcid":false,"given":"David B.","family":"Beck","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6668-8854","authenticated-orcid":false,"given":"Sophie","family":"Georgin-Lavialle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9488-661X","authenticated-orcid":false,"given":"Yohei","family":"Kirino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhavisha A.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1122-1231","authenticated-orcid":false,"given":"Samuele","family":"Ferrari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,16]]},"reference":[{"key":"695_CR1","doi-asserted-by":"publisher","first-page":"2628","DOI":"10.1056\/NEJMoa2026834","volume":"383","author":"DB Beck","year":"2020","unstructured":"Beck, D. B. et al. Somatic mutations in UBA1 and severe adult-onset autoinflammatory disease. N. Engl. J. Med. 383, 2628\u20132638 (2020). Seminal paper describing VEXAS as a distinct clinical entity caused by UBA1 mutations.","journal-title":"N. Engl. J. Med."},{"key":"695_CR2","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.ajhg.2007.09.009","volume":"82","author":"J Ramser","year":"2008","unstructured":"Ramser, J. et al. Rare missense and synonymous variants in UBE1 are associated with X-linked infantile spinal muscular atrophy. Am. J. Hum. Genet. 82, 188\u2013193 (2008).","journal-title":"Am. J. Hum. Genet."},{"key":"695_CR3","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1038\/s41588-021-00920-0","volume":"53","author":"T Zhang","year":"2021","unstructured":"Zhang, T. et al. Genomic and evolutionary classification of lung cancer in never smokers. Nat. Genet. 53, 1348\u20131359 (2021).","journal-title":"Nat. Genet."},{"key":"695_CR4","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1001\/jama.2022.24836","volume":"329","author":"DB Beck","year":"2023","unstructured":"Beck, D. B. et al. Estimated prevalence and clinical manifestations of UBA1 variants associated with VEXAS syndrome in a clinical population. JAMA 329, 318\u2013324 (2023).","journal-title":"JAMA"},{"key":"695_CR5","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1002\/art.42802","volume":"76","author":"RW Corty","year":"2024","unstructured":"Corty, R. W. et al. VEXAS-defining UBA1 somatic variants in 245,368 diverse individuals in the NIH All Of Us cohort. Arthritis Rheumatol. 76, 942\u2013948 (2024).","journal-title":"Arthritis Rheumatol."},{"key":"695_CR6","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1111\/bjh.20176","volume":"208","author":"A Martinez Rodriguez","year":"2026","unstructured":"Martinez Rodriguez, A. et al. Mapping VEXAS-associated and rare UBA1 variants in the United Kingdom: insights from patient cohorts and the general population. Br. J. Haematol. 208, 116\u2013128 (2026).","journal-title":"Br. J. Haematol."},{"key":"695_CR7","doi-asserted-by":"publisher","first-page":"2872","DOI":"10.1038\/s41375-025-02775-4","volume":"39","author":"M Sakuma","year":"2025","unstructured":"Sakuma, M. et al. Distinct characteristics of VEXAS-causative UBA1 M41 and recurrent functional non-M41 mutations. Leukemia 39, 2872\u20132880\u00a0(2025). This paper compares clinical manifestations in Met41 and non-Met41 mutations in a large cohort of patients with VEXAS, with higher incidence of severe haematological manifestations in the latter.","journal-title":"Leukemia"},{"key":"695_CR8","doi-asserted-by":"publisher","first-page":"2056","DOI":"10.1093\/rheumatology\/kead425","volume":"63","author":"A Maeda","year":"2024","unstructured":"Maeda, A. et al. Efficient detection of somatic UBA1 variants and clinical scoring system predicting patients with variants in VEXAS syndrome. Rheumatology\u00a063, 2056\u20132064 (2024).","journal-title":"Rheumatology"},{"key":"695_CR9","doi-asserted-by":"publisher","first-page":"E402","DOI":"10.1093\/rheumatology\/keab392","volume":"60","author":"T Barba","year":"2021","unstructured":"Barba, T. et al. VEXAS syndrome in a woman. Rheumatology\u00a060, E402\u2013E403 (2021).","journal-title":"Rheumatology"},{"key":"695_CR10","doi-asserted-by":"publisher","first-page":"2694","DOI":"10.1093\/rheumatology\/keae123","volume":"63","author":"R Echerbault","year":"2024","unstructured":"Echerbault, R. et al. Comparing clinical features between males and females with VEXAS syndrome: data from literature analysis of patient reports. Rheumatology\u00a063, 2694\u20132700 (2024).","journal-title":"Rheumatology"},{"key":"695_CR11","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1111\/joim.70023","volume":"298","author":"R Bourguiba","year":"2025","unstructured":"Bourguiba, R. et al. Characterizing VEXAS syndrome in women: findings from an international multicenter study. J. Intern. Med. 298, 516\u2013524\u00a0(2025).","journal-title":"J. Intern. Med."},{"key":"695_CR12","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1002\/art.43327","volume":"78","author":"M Anderson","year":"2026","unstructured":"Anderson, M. et al. Clinical manifestations of VEXAS syndrome across a broad spectrum of UBA1 mutation burden. Arthritis Rheumatol. 78, 223\u2013230 (2026).","journal-title":"Arthritis Rheumatol."},{"key":"695_CR13","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1182\/blood.2022016985","volume":"140","author":"MA Ferrada","year":"2022","unstructured":"Ferrada, M. A. et al. Translation of cytoplasmic UBA1 contributes to VEXAS syndrome pathogenesis. Blood 140, 1496\u20131506 (2022).","journal-title":"Blood"},{"key":"695_CR14","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1111\/bjd.20805","volume":"186","author":"S Georgin-Lavialle","year":"2022","unstructured":"Georgin-Lavialle, S. et al. Further characterization of clinical and laboratory features in VEXAS syndrome: large-scale analysis of a multicentre case series of 116 French patients. Br. J. Dermatol. 186, 564\u2013574 (2022).","journal-title":"Br. J. Dermatol."},{"key":"695_CR15","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1093\/mr\/roaf095","volume":"36","author":"A Maeda","year":"2025","unstructured":"Maeda, A. et al. High glucocorticoid dependency and limited therapeutic response in Japanese patients with VEXAS syndrome: a multicentre retrospective study. Mod. Rheumatol. 36, 307\u2013312 (2025).","journal-title":"Mod. Rheumatol."},{"key":"695_CR16","doi-asserted-by":"publisher","first-page":"3872","DOI":"10.1093\/rheumatology\/keae530","volume":"64","author":"Y Kirino","year":"2025","unstructured":"Kirino, Y. et al. Low remission rates and high incidence of adverse events in a prospective VEXAS syndrome registry. Rheumatology\u00a064, 3872\u20133878 (2025). Prospective registry study on clinical outcomes in a cohort of patients with VEXAS.","journal-title":"Rheumatology"},{"key":"695_CR17","unstructured":"Hadjadj, J. & Beck, D. VEXAS Syndrome. in GeneReviews [Internet] https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK614471\/ (2025)."},{"key":"695_CR18","first-page":"85","volume":"85","author":"BA Turturice","year":"2025","unstructured":"Turturice, B. A. et al. Disease trajectories and glucocorticoid exposure in VEXAS syndrome treated with cytokine-directed therapies. Ann. Rheum. Dis. 85, 370\u2013378\u00a0(2025).","journal-title":"Ann. Rheum. Dis."},{"key":"695_CR19","doi-asserted-by":"publisher","DOI":"10.1093\/rap\/rkae065","volume":"8","author":"S Adachi","year":"2024","unstructured":"Adachi, S. et al. Targeting enhanced cell death represents a potential therapeutic strategy for VEXAS syndrome. Rheumatol. Adv. Pract. 8, rkae065 (2024).","journal-title":"Rheumatol. Adv. Pract."},{"key":"695_CR20","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-59890-0","volume":"16","author":"H Mizumaki","year":"2025","unstructured":"Mizumaki, H. et al. In depth transcriptomic profiling defines a landscape of dysfunctional immune responses in patients with VEXAS syndrome. Nat. Commun. 16, 4690 (2025).","journal-title":"Nat. Commun."},{"key":"695_CR21","doi-asserted-by":"publisher","first-page":"1950","DOI":"10.1182\/blood.2024028216","volume":"146","author":"P Breillat","year":"2025","unstructured":"Breillat, P. et al. Impaired cytotoxic function and exhausted phenotype of natural killer cells in VEXAS syndrome. Blood 146, 1950\u20131963 (2025).","journal-title":"Blood"},{"key":"695_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-44811-4","volume":"15","author":"O Kosmider","year":"2024","unstructured":"Kosmider, O. et al. VEXAS syndrome is characterized by inflammasome activation and monocyte dysregulation. Nat. Commun. 15, 910 (2024). This paper describes inflammasome activation and immune dysregulation as hallmarks of myeloid-driven inflammation in VEXAS.","journal-title":"Nat. Commun."},{"key":"695_CR23","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1038\/nrm.2017.83","volume":"19","author":"M Rape","year":"2018","unstructured":"Rape, M. Ubiquitylation at the crossroads of development and disease. Nat. Rev. Mol. Cell Biol. 19, 59\u201370 (2018).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"695_CR24","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1002\/j.1460-2075.1991.tb07940.x","volume":"10","author":"JP McGrath","year":"1991","unstructured":"McGrath, J. P., Jentsch, S. & Varshavsky, A. UBA1: an essential yeast gene encoding ubiquitin-activating enzyme. EMBO J. 10, 227\u2013236 (1991).","journal-title":"EMBO J."},{"key":"695_CR25","doi-asserted-by":"publisher","unstructured":"Ganesan S. et al. Single-cell genotype-phenotype mapping identifies therapeutic vulnerabilities in VEXAS syndrome. Preprint at bioRxiv https:\/\/doi.org\/10.1101\/2024.05.19.594376 (2024). This paper identifies the PERK UPR axis as functional vulnerability in UBA1-mutant cells through single-cell multi-omics profiling.","DOI":"10.1101\/2024.05.19.594376"},{"key":"695_CR26","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1182\/blood-2024-202567","volume":"144","author":"SJ Magaziner","year":"2024","unstructured":"Magaziner, S. J. et al. The mechanism of cell autonomous inflammation in VEXAS syndrome Is mediated by proteotoxic stress [abstract]. Blood 144, 187 (2024).","journal-title":"Blood"},{"key":"695_CR27","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1038\/s44318-024-00046-z","volume":"43","author":"JC Collins","year":"2024","unstructured":"Collins, J. C. et al. Shared and distinct mechanisms of UBA1 inactivation across different diseases. EMBO J. 43, 1919\u20131946 (2024).","journal-title":"EMBO J."},{"key":"695_CR28","doi-asserted-by":"publisher","first-page":"1911","DOI":"10.1038\/s41591-025-03623-9","volume":"31","author":"R Molteni","year":"2025","unstructured":"Molteni, R. et al. Mechanisms of hematopoietic clonal dominance in VEXAS syndrome. Nat. Med. 31, 1911\u20131924 (2025). This paper describes in vitro and in vivo humanized models of VEXAS and exploits them to describe how UBA1-mutant haematopoietic clones may acquire dominance over wild-type haematopoiesis.","journal-title":"Nat. Med."},{"key":"695_CR29","doi-asserted-by":"publisher","DOI":"10.1051\/rmr\/170005","volume":"6","author":"H Abdellatif","year":"2018","unstructured":"Abdellatif, H. Circulating CD34+ hematopoietic stem\/progenitor cells paralleled with level of viremia in patients chronically infected with hepatitis B virus. Regen. Med. Res. 6, 1 (2018).","journal-title":"Regen. Med. Res."},{"key":"695_CR30","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1182\/blood-2023-190210","volume":"142","author":"F Gutierrez-Rodrigues","year":"2023","unstructured":"Gutierrez-Rodrigues, F. et al. Spectrum of clonal hematopoiesis in VEXAS syndrome. Blood J. 142, 244\u2013259 (2023). This paper describes the heterogeneous interplay between CHIP mutations in patients with VEXAS and their correlation with clinical outcomes.","journal-title":"Blood J."},{"key":"695_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2023.101160","volume":"4","author":"Z Wu","year":"2023","unstructured":"Wu, Z. et al. Early activation of inflammatory pathways in UBA1-mutated hematopoietic stem and progenitor cells in VEXAS. Cell. Rep. Med. 4, 101160 (2023).","journal-title":"Cell. Rep. Med."},{"key":"695_CR32","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1182\/blood.2025029081","volume":"147","author":"F Rodrigues","year":"2026","unstructured":"Rodrigues, F. et al. VEXAS anemia is a mosaic erythroblastopenia. Blood\u00a0147, 1178\u20131190 (2026).","journal-title":"Blood"},{"key":"695_CR33","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1038\/s41586-025-09815-0","volume":"649","author":"VK Narendra","year":"2026","unstructured":"Narendra, V. K. et al. Independent mechanisms of inflammation and myeloid bias in VEXAS syndrome. Nature 649, 1273\u20131281 (2026).","journal-title":"Nature"},{"key":"695_CR34","doi-asserted-by":"publisher","DOI":"10.1182\/BLOOD.2025031593","author":"P Breillat","year":"2026","unstructured":"Breillat, P. et al. Inflammatory cell death and monocyte dysfunction in VEXAS syndrome. Blood\u00a0https:\/\/doi.org\/10.1182\/blood.2025031593 (2026).","journal-title":"Blood"},{"key":"695_CR35","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1038\/s41591-020-0752-4","volume":"26","author":"M Reyes","year":"2020","unstructured":"Reyes, M. et al. An immune-cell signature of bacterial sepsis. Nat. Med. 26, 333\u2013340 (2020).","journal-title":"Nat. Med."},{"key":"695_CR36","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1016\/j.stem.2024.05.010","volume":"31","author":"NA Jakobsen","year":"2024","unstructured":"Jakobsen, N. A. et al. Selective advantage of mutant stem cells in human clonal hematopoiesis is associated with attenuated response to inflammation and aging. Cell Stem Cell 31, 1127\u20131144.e17 (2024).","journal-title":"Cell Stem Cell"},{"key":"695_CR37","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1126\/science.aba9304","volume":"374","author":"S Avagyan","year":"2021","unstructured":"Avagyan, S. et al. Resistance to inflammation underlies enhanced fitness in clonal hematopoiesis. Science 374, 768\u2013772 (2021).","journal-title":"Science"},{"key":"695_CR38","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1038\/nm.3733","volume":"20","author":"M Xie","year":"2014","unstructured":"Xie, M. et al. Age-related mutations associated with clonal hematopoietic expansion and malignancies. Nat. Med. 20, 1472\u20131478 (2014).","journal-title":"Nat. Med."},{"key":"695_CR39","doi-asserted-by":"publisher","first-page":"2488","DOI":"10.1056\/NEJMoa1408617","volume":"371","author":"S Jaiswal","year":"2014","unstructured":"Jaiswal, S. et al. Age-related clonal hematopoiesis associated with adverse outcomes. N. Engl. J. Med. 371, 2488\u20132498 (2014).","journal-title":"N. Engl. J. Med."},{"key":"695_CR40","doi-asserted-by":"publisher","first-page":"2477","DOI":"10.1056\/NEJMoa1409405","volume":"371","author":"G Genovese","year":"2014","unstructured":"Genovese, G. et al. Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. N. Engl. J. Med. 371, 2477\u20132487 (2014).","journal-title":"N. Engl. J. Med."},{"key":"695_CR41","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1002\/art.43287","volume":"78","author":"AM Mekinian","year":"2026","unstructured":"Mekinian, A. M. et al. American College of Rheumatology guidance statement for diagnosis and management of VEXAS developed by the International VEXAS Working Group Expert Panel. Arthritis Rheumatol. 78, 509\u2013522\u00a0(2026). Updated clinical guidelines on diagnosis and management of VEXAS.","journal-title":"Arthritis Rheumatol."},{"key":"695_CR42","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-025-01932-9","volume":"45","author":"L von Bornemann Fl\u00f8e","year":"2025","unstructured":"von Bornemann Fl\u00f8e, L. et al. Diagnostic and monitoring strategies for VEXAS syndrome: evaluating Sanger sequencing, NGS, and the SWIM-score. J. Clin. Immunol. 45, 138 (2025).","journal-title":"J. Clin. Immunol."},{"key":"695_CR43","doi-asserted-by":"publisher","first-page":"5217","DOI":"10.1093\/rheumatology\/keaf293","volume":"64","author":"A Al-Hakim","year":"2025","unstructured":"Al-Hakim, A. et al. Clinical features in VEXAS syndrome: a systematic review. Rheumatology\u00a064, 5217\u20135229 (2025).","journal-title":"Rheumatology"},{"key":"695_CR44","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1002\/art.41992","volume":"74","author":"F Muratore","year":"2022","unstructured":"Muratore, F. et al. VEXAS syndrome: a case series from a single-center cohort of Italian patients with vasculitis. Arthritis Rheumatol. 74, 665\u2013670 (2022).","journal-title":"Arthritis Rheumatol."},{"key":"695_CR45","doi-asserted-by":"publisher","first-page":"3889","DOI":"10.1093\/rheumatology\/keae550","volume":"64","author":"MM Sullivan","year":"2025","unstructured":"Sullivan, M. M. et al. Vasculitis associated with VEXAS syndrome. Rheumatology\u00a064, 3889\u20133894 (2025).","journal-title":"Rheumatology"},{"key":"695_CR46","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1001\/jamadermatol.2021.3344","volume":"157","author":"E Zakine","year":"2021","unstructured":"Zakine, E. et al. UBA1 variations in neutrophilic dermatosis skin lesions of patients with VEXAS syndrome. JAMA Dermatol. 157, 1349\u20131354 (2021).","journal-title":"JAMA Dermatol."},{"key":"695_CR47","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1016\/j.jaad.2022.10.052","volume":"88","author":"\u00c8 Zakine","year":"2023","unstructured":"Zakine, \u00c8. et al. Clinical and pathological features of cutaneous manifestations in VEXAS syndrome: a multicenter retrospective study of 59 cases. J. Am. Acad. Dermatol. 88, 917\u2013920 (2023).","journal-title":"J. Am. Acad. Dermatol."},{"key":"695_CR48","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1111\/ijd.16635","volume":"62","author":"AS Hines","year":"2023","unstructured":"Hines, A. S. et al. Cutaneous involvement in VEXAS syndrome: clinical and histopathologic findings. Int. J. Dermatol. 62, 938\u2013945 (2023).","journal-title":"Int. J. Dermatol."},{"key":"695_CR49","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1001\/jamadermatol.2024.1657","volume":"160","author":"IJ Tan","year":"2024","unstructured":"Tan, I. J. et al. Skin manifestations of VEXAS syndrome and associated genotypes. JAMA Dermatol. 160, 822\u2013829 (2024).","journal-title":"JAMA Dermatol."},{"key":"695_CR50","doi-asserted-by":"publisher","first-page":"E271","DOI":"10.1093\/rheumatology\/kead076","volume":"62","author":"L Valor-M\u00e9ndez","year":"2023","unstructured":"Valor-M\u00e9ndez, L. et al. VEXAS syndrome mimicking lupus-like disease. Rheumatology\u00a062, E271\u2013E272 (2023).","journal-title":"Rheumatology"},{"key":"695_CR51","doi-asserted-by":"publisher","DOI":"10.2340\/actadv.v103.18284","volume":"103","author":"J Gil-Lianes","year":"2023","unstructured":"Gil-Lianes, J. et al. Sweet syndrome: clinical presentation, malignancy association, autoinflammatory disorders and treatment response in a cohort of 93 patients with long-term follow-up. Acta Derm. Venereol. 103, adv18284 (2023).","journal-title":"Acta Derm. Venereol."},{"key":"695_CR52","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1001\/jamadermatol.2025.0034","volume":"161","author":"C Grolleau","year":"2025","unstructured":"Grolleau, C. et al. Inflammatory signatures in VEXAS syndrome, myelodysplasia cutis, and Sweet syndrome. JAMA Dermatol. 161, 538\u2013543 (2025).","journal-title":"JAMA Dermatol."},{"key":"695_CR53","doi-asserted-by":"publisher","first-page":"3203","DOI":"10.1182\/bloodadvances.2021004976","volume":"5","author":"IE Obiorah","year":"2021","unstructured":"Obiorah, I. E. et al. Benign and malignant hematologic manifestations in patients with VEXAS syndrome due to somatic mutations in UBA1. Blood Adv. 5, 3203\u20133215 (2021).","journal-title":"Blood Adv."},{"key":"695_CR54","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1093\/ajcp\/aqad186","volume":"161","author":"H Olteanu","year":"2024","unstructured":"Olteanu, H. et al. Comprehensive morphologic characterization of bone marrow biopsy findings in a large cohort of patients with VEXAS syndrome: a single-institution longitudinal study of 111 bone marrow samples from 52 patients. Am. J. Clin. Pathol. 161, 609\u2013624 (2024).","journal-title":"Am. J. Clin. Pathol."},{"key":"695_CR55","doi-asserted-by":"publisher","first-page":"1886","DOI":"10.1002\/art.41743","volume":"73","author":"MA Ferrada","year":"2021","unstructured":"Ferrada, M. A. et al. Somatic mutations in UBA1 define a distinct subset of relapsing polychondritis patients with VEXAS. Arthritis Rheumatol. 73, 1886\u20131895 (2021).","journal-title":"Arthritis Rheumatol."},{"key":"695_CR56","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1136\/ard-2023-224819","volume":"83","author":"B De Valence","year":"2024","unstructured":"De Valence, B. et al. Serious infections in patients with VEXAS syndrome: data from the French VEXAS registry. Ann. Rheum. Dis. 83, 372\u2013381 (2024).","journal-title":"Ann. Rheum. Dis."},{"key":"695_CR57","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofae405","volume":"11","author":"M Czech","year":"2024","unstructured":"Czech, M. et al. Opportunistic infections, mortality risk, and prevention strategies in patients with vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic (VEXAS) syndrome. Open Forum Infect. Dis. 11, ofae405 (2024).","journal-title":"Open Forum Infect. Dis."},{"key":"695_CR58","doi-asserted-by":"publisher","first-page":"e734","DOI":"10.1016\/S2665-9913(25)00225-5","volume":"7","author":"V Ribier","year":"2025","unstructured":"Ribier, V. et al. Mapping the infectious burden in VEXAS syndrome: a systematic review and rationale for prevention. Lancet Rheumatol. 7, e734\u2013e744 (2025).","journal-title":"Lancet Rheumatol."},{"key":"695_CR59","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1182\/blood.2023023723","volume":"144","author":"M Sirenko","year":"2024","unstructured":"Sirenko, M. et al. Molecular and clinical presentation of UBA1-mutated myelodysplastic syndromes. Blood 144, 1221\u20131229 (2024).","journal-title":"Blood"},{"key":"695_CR60","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1038\/s41375-023-01857-5","volume":"37","author":"M Sakuma","year":"2023","unstructured":"Sakuma, M. et al. Novel causative variants of VEXAS in UBA1 detected through whole genome transcriptome sequencing in a large cohort of hematological malignancies. Leukemia 37, 1080\u20131091 (2023).","journal-title":"Leukemia"},{"key":"695_CR61","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1038\/s41375-025-02858-2","volume":"40","author":"LP Zhao","year":"2026","unstructured":"Zhao, L. P. et al. Characteristics and prognostic significance of myelodysplasia-related features in VEXAS syndrome. Leukemia 40, 661\u2013665 (2026).","journal-title":"Leukemia"},{"key":"695_CR62","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1002\/ajh.27169","volume":"99","author":"C Gurnari","year":"2024","unstructured":"Gurnari, C. et al. Diagnostic capabilities, clinical features, and longitudinal UBA1 clonal dynamics of a nationwide VEXAS cohort. Am. J. Hematol. 99, 254\u2013262 (2024).","journal-title":"Am. J. Hematol."},{"key":"695_CR63","doi-asserted-by":"publisher","first-page":"3685","DOI":"10.1182\/blood.2021010811","volume":"137","author":"C Gurnari","year":"2021","unstructured":"Gurnari, C. et al. Vacuolization of hematopoietic precursors: an enigma with multiple etiologies. Blood 137, 3685\u20133689 (2021).","journal-title":"Blood"},{"key":"695_CR64","doi-asserted-by":"publisher","first-page":"3947","DOI":"10.1093\/rheumatology\/kead245","volume":"62","author":"AS Hines","year":"2023","unstructured":"Hines, A. S. et al. Targeted testing of bone marrow specimens with cytoplasmic vacuolization to identify previously undiagnosed cases of VEXAS syndrome. Rheumatology\u00a062, 3947\u20133951 (2023).","journal-title":"Rheumatology"},{"key":"695_CR65","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000828","volume":"7","author":"A Rabut","year":"2023","unstructured":"Rabut, A. et al. Quantitative assessment of vacuolization of myeloid precursors in VEXAS syndrome. Hemasphere 7, E828 (2023).","journal-title":"Hemasphere"},{"key":"695_CR66","doi-asserted-by":"publisher","first-page":"6152","DOI":"10.1182\/bloodadvances.2023010456","volume":"7","author":"Y Ding","year":"2023","unstructured":"Ding, Y. et al. Use of flow cytometric light scattering to recognize the characteristic vacuolated marrow cells in VEXAS syndrome. Blood Adv. 7, 6152\u20136155 (2023).","journal-title":"Blood Adv."},{"key":"695_CR67","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26168044","volume":"26","author":"A Takami","year":"2025","unstructured":"Takami, A. et al. Vacuolated marrow cytopenias from copper deficiency to UBA1-mutant VEXAS: molecular landscape, systematic review, and cost-efficient diagnostic algorithm. Int. J. Mol. Sci. 26, 8044 (2025).","journal-title":"Int. J. Mol. Sci."},{"key":"695_CR68","doi-asserted-by":"publisher","first-page":"e160","DOI":"10.1016\/S2352-3026(23)00375-7","volume":"11","author":"V Lacombe","year":"2024","unstructured":"Lacombe, V. et al. Vacuoles in bone marrow progenitors: VEXAS syndrome and beyond. Lancet Haematol. 11, e160\u2013e167 (2024).","journal-title":"Lancet Haematol."},{"key":"695_CR69","doi-asserted-by":"publisher","first-page":"2190","DOI":"10.1182\/blood.2023022329","volume":"143","author":"Y Kusne","year":"2024","unstructured":"Kusne, Y. et al. Venous and arterial thrombosis in patients with VEXAS syndrome. Blood 143, 2190\u20132200 (2024).","journal-title":"Blood"},{"key":"695_CR70","doi-asserted-by":"publisher","first-page":"E269","DOI":"10.1093\/rheumatology\/kead168","volume":"62","author":"H Karadeniz","year":"2023","unstructured":"Karadeniz, H., Cerit, M., G\u00fcler, A. A., Tufan, A. & Kanthi, Y. Venous inflammation might be one of the features of VEXAS syndrome and associated thrombosis. Rheumatology\u00a062, E269\u2013E270 (2023).","journal-title":"Rheumatology"},{"key":"695_CR71","first-page":"S2","volume":"30","author":"JS Smolen","year":"2012","unstructured":"Smolen, J. S. Treat-to-target: rationale and strategies. Clin. Exp. Rheumatol. 30, S2\u2013S6 (2012).","journal-title":"Clin. Exp. Rheumatol."},{"key":"695_CR72","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.ard.2025.05.767","volume":"84","author":"K Byram","year":"2025","unstructured":"Byram, K. et al. Development of a disease activity index for the assessment of VEXAS syndrome (VEXAS-DAI) [abstract POS0381]. Ann. Rheum. Dis. 84, 625\u2013626 (2025).","journal-title":"Ann. Rheum. Dis."},{"key":"695_CR73","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2025.103354","volume":"86","author":"F Efficace","year":"2025","unstructured":"Efficace, F. et al. Exploring patient-reported outcomes and morbidity burden of patients with VEXAS syndrome: a scoping review. EClinicalMedicine 86, 103354 (2025).","journal-title":"EClinicalMedicine"},{"key":"695_CR74","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.ard.2025.05.295","volume":"84","author":"Y Kirino","year":"2025","unstructured":"Kirino, Y. et al. Multi-omics analysis integrated with prospective registry data identifies rnase1 associated with disease activity in VEXAS syndrome [abstract OP0285]. Ann. Rheum. Dis. 84, 234\u2013235 (2025).","journal-title":"Ann. Rheum. Dis."},{"key":"695_CR75","doi-asserted-by":"publisher","unstructured":"Higashitani K. et al. RIPK3\u2013RNASE1 axis as a potential therapeutic and clinical monitoring target in VEXAS syndrome. Preprint at bioRxiv https:\/\/doi.org\/10.64898\/2026.02.04.703672 (2026).","DOI":"10.64898\/2026.02.04.703672"},{"key":"695_CR76","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.3390\/jcm15041426","volume":"15","author":"DB Beck","year":"2026","unstructured":"Beck, D. B. et al. PAXIS: a randomized, double-blind, placebo-controlled, dose finding phase 2 study (part 1) followed by an open-label period (part 2) to assess the efficacy and safety of pacritinib in patients with VEXAS syndrome. J. Clin. Med. 15, 1426 (2026).","journal-title":"J. Clin. Med."},{"key":"695_CR77","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT06538181 (2025)."},{"key":"695_CR78","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1136\/ard-2024-225640","volume":"83","author":"J Hadjadj","year":"2024","unstructured":"Hadjadj, J. et al. Efficacy and safety of targeted therapies in VEXAS syndrome: retrospective study from the FRENVEX. Ann. Rheum. Dis. 83, 1358\u20131367 (2024). Retrospective study on the use of targeted anti-inflammatory therapies in patients with VEXAS showing higher clinical benefit for JAK and IL-6 inhibitors.","journal-title":"Ann. Rheum. Dis."},{"key":"695_CR79","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1182\/blood.2022016642","volume":"140","author":"M Heiblig","year":"2022","unstructured":"Heiblig, M. et al. Ruxolitinib is more effective than other JAK inhibitors to treat VEXAS syndrome: a retrospective multicenter study. Blood 140, 927\u2013931 (2022).","journal-title":"Blood"},{"key":"695_CR80","doi-asserted-by":"publisher","first-page":"e472","DOI":"10.1016\/S2665-9913(25)00034-7","volume":"7","author":"A Al-Hakim","year":"2025","unstructured":"Al-Hakim, A. et al. Treatment outcomes in patients with VEXAS syndrome: a retrospective cohort study. Lancet Rheumatol. 7, e472\u2013e484 (2025).","journal-title":"Lancet Rheumatol."},{"key":"695_CR81","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1007\/s00277-024-06037-8","volume":"104","author":"B C\u00e1ceres-Nazario","year":"2025","unstructured":"C\u00e1ceres-Nazario, B., Rivenbark, J., Saha, M. K., Mathews, S. & Rubinstein, S. M. Novel use of siltuximab in a patient with VEXAS syndrome. Ann. Hematol. 104, 1259\u20131267 (2025).","journal-title":"Ann. Hematol."},{"key":"695_CR82","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1002\/art.43384","volume":"78","author":"T Eviatar","year":"2025","unstructured":"Eviatar, T. et al. Comparative efficacy and safety of anakinra and canakinumab in patients with VEXAS syndrome - an international multicenter study. Arthritis Rheumatol. 78, 475\u2013482 (2025).","journal-title":"Arthritis Rheumatol."},{"key":"695_CR83","doi-asserted-by":"publisher","first-page":"2739","DOI":"10.1038\/s41375-022-01698-8","volume":"36","author":"A Mekinian","year":"2022","unstructured":"Mekinian, A. et al. A phase II prospective trial of azacitidine in steroid-dependent or refractory systemic autoimmune\/inflammatory disorders and VEXAS syndrome associated with MDS and CMML. Leukemia 36, 2739\u20132742 (2022).","journal-title":"Leukemia"},{"key":"695_CR84","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1111\/bjh.17893","volume":"196","author":"T Comont","year":"2022","unstructured":"Comont, T. et al. Azacitidine for patients with vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic syndrome (VEXAS) and myelodysplastic syndrome: data from the French VEXAS registry. Br. J. Haematol. 196, 969\u2013974 (2022).","journal-title":"Br. J. Haematol."},{"key":"695_CR85","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000661","volume":"5","author":"MHGP Raaijmakers","year":"2021","unstructured":"Raaijmakers, M. H. G. P. et al. Azacytidine treatment for VEXAS syndrome. Hemasphere 5, E661 (2021).","journal-title":"Hemasphere"},{"key":"695_CR86","doi-asserted-by":"publisher","first-page":"3431","DOI":"10.3324\/haematol.2024.285519","volume":"109","author":"R Trikha","year":"2024","unstructured":"Trikha, R. et al. De-escalation of corticosteroids and clonal remission in UBA1 mutation-driven VEXAS syndrome with 5-azacytidine. Haematologica 109, 3431\u20133434 (2024).","journal-title":"Haematologica"},{"key":"695_CR87","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1182\/blood.2024028133","volume":"146","author":"V Jachiet","year":"2025","unstructured":"Jachiet, V. et al. Efficacy and safety of azacitidine for VEXAS syndrome: a large-scale retrospective study from FRENVEX. Blood 146, 1450\u20131461 (2025). Retrospective study showing that the use of azacitidine often reduces the VAF of the mutant UBA1 clone and is clinically safe and efficacious in >60% of patients.","journal-title":"Blood"},{"key":"695_CR88","doi-asserted-by":"publisher","DOI":"10.1002\/hem3.129","volume":"8","author":"AM Aalbers","year":"2024","unstructured":"Aalbers, A. M., van Daele, P. L. A., Dalm, V. A. S. H., Valk, P. J. M. & Raaijmakers, M. H. G. P. Long-term genetic and clinical remissions after cessation of azacitidine treatment in patients with VEXAS syndrome. Hemasphere 8, e129 (2024).","journal-title":"Hemasphere"},{"key":"695_CR89","first-page":"1432","volume":"110","author":"LP Zhao","year":"2025","unstructured":"Zhao, L. P. et al. Very long-term remission with azacitidine in VEXAS syndrome. Haematologica\u00a0110, 1432\u20131435 (2025).","journal-title":"Haematologica"},{"key":"695_CR90","doi-asserted-by":"publisher","first-page":"4095","DOI":"10.1002\/cncr.34492","volume":"128","author":"S Park","year":"2022","unstructured":"Park, S. et al. Five-day versus 7-day treatment regimen with azacitidine in lower risk myelodysplastic syndrome: a phase 2, multicenter, randomized trial. Cancer 128, 4095\u20134108 (2022).","journal-title":"Cancer"},{"key":"695_CR91","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1182\/bloodadvances.2023012478","volume":"8","author":"C Gurnari","year":"2024","unstructured":"Gurnari, C. et al. Allogeneic hematopoietic cell transplantation for VEXAS syndrome: results of a multicenter study of the EBMT. Blood Adv. 8, 1444\u20131448 (2024).","journal-title":"Blood Adv."},{"key":"695_CR92","doi-asserted-by":"publisher","first-page":"E28","DOI":"10.1002\/ajh.26786","volume":"98","author":"AA Mangaonkar","year":"2023","unstructured":"Mangaonkar, A. A. et al. Reduced intensity conditioning allogeneic hematopoietic stem cell transplantation in VEXAS syndrome: data from a prospective series of patients. Am. J. Hematol. 98, E28\u2013E31 (2023).","journal-title":"Am. J. Hematol."},{"key":"695_CR93","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT05027945 (2026)."},{"key":"695_CR94","first-page":"339","volume":"110","author":"N Kr\u00f6ger","year":"2025","unstructured":"Kr\u00f6ger, N. Treatment of high-risk myelodysplastic syndromes. Haematologica 110, 339\u2013349 (2025).","journal-title":"Haematologica"},{"key":"695_CR95","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2025.1462254","volume":"16","author":"A Vitale","year":"2025","unstructured":"Vitale, A. et al. Efficacy and safety profile of biotechnological agents and Janus kinase inhibitors in VEXAS syndrome: data from the international AIDA Network VEXAS registry. Front. Pharmacol. 16, 1462254 (2025).","journal-title":"Front. Pharmacol."},{"key":"695_CR96","doi-asserted-by":"publisher","first-page":"3565","DOI":"10.1007\/s10067-024-07160-7","volume":"43","author":"SB Ali","year":"2024","unstructured":"Ali, S. B. & Gurnari, C. Allogenic haematopoietic stem cell transplantation in VEXAS: a review of 33 patients. Clin. Rheumatol. 43, 3565\u20133575 (2024).","journal-title":"Clin. Rheumatol."},{"key":"695_CR97","doi-asserted-by":"publisher","first-page":"3518","DOI":"10.1093\/rheumatology\/kead240","volume":"62","author":"Z Boyadzhieva","year":"2023","unstructured":"Boyadzhieva, Z., Ruffer, N., K\u00f6tter, I. & Krusche, M. How to treat VEXAS syndrome: a systematic review on effectiveness and safety of current treatment strategies. Rheumatology\u00a062, 3518\u20133525 (2023).","journal-title":"Rheumatology"},{"key":"695_CR98","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1007\/s12185-024-03799-9","volume":"122","author":"H Nakajima","year":"2024","unstructured":"Nakajima, H. & Kunimoto, H. VEXAS syndrome. Int. J. Hematol. 122, 341\u2013350 (2024).","journal-title":"Int. J. Hematol."},{"key":"695_CR99","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1007\/s11739-023-03193-z","volume":"18","author":"A Vitale","year":"2023","unstructured":"Vitale, A. et al. VEXAS syndrome: a new paradigm for adult-onset monogenic autoinflammatory diseases. Intern. Emerg. Med. 18, 711\u2013722 (2023).","journal-title":"Intern. Emerg. Med."},{"key":"695_CR100","doi-asserted-by":"publisher","first-page":"3711","DOI":"10.1182\/blood-2024-205755","volume":"144","author":"BA Patel","year":"2024","unstructured":"Patel, B. A. et al. Patient reported outcomes in Vexas syndrome [abstract]. Blood 144, 3711\u20133712 (2024).","journal-title":"Blood"},{"key":"695_CR101","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1002\/acr.23492","volume":"70","author":"MA Ferrada","year":"2018","unstructured":"Ferrada, M. A. et al. Patient perception of disease-related symptoms and complications in relapsing polychondritis. Arthritis Care Res.\u00a070, 1124\u20131131 (2018).","journal-title":"Arthritis Care Res."},{"key":"695_CR102","doi-asserted-by":"publisher","first-page":"3506","DOI":"10.1182\/bloodadvances.2022009000","volume":"7","author":"GA Abel","year":"2023","unstructured":"Abel, G. A. et al. Health-related quality of life and vulnerability among people with myelodysplastic syndromes: a US national study. Blood Adv. 7, 3506\u20133515 (2023).","journal-title":"Blood Adv."},{"key":"695_CR103","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.jaad.2016.02.1241","volume":"76","author":"A Caplan","year":"2017","unstructured":"Caplan, A., Fett, N., Rosenbach, M., Werth, V. P. & Micheletti, R. G. Prevention and management of glucocorticoid-induced side effects: a comprehensive review: ocular, cardiovascular, muscular, and psychiatric side effects and issues unique to pediatric patients. J. Am. Acad. Dermatol. 76, 201\u2013207 (2017).","journal-title":"J. Am. Acad. Dermatol."},{"key":"695_CR104","doi-asserted-by":"publisher","first-page":"623","DOI":"10.3390\/ijms22020623","volume":"22","author":"C Beaupere","year":"2021","unstructured":"Beaupere, C., Liboz, A., F\u00e8ve, B., Blondeau, B. & Guillemain, G. Molecular mechanisms of glucocorticoid-induced insulin resistance. Int. J. Mol. Sci. 22, 623 (2021).","journal-title":"Int. J. Mol. Sci."},{"key":"695_CR105","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1093\/rheumatology\/keaa289","volume":"60","author":"L Fardet","year":"2021","unstructured":"Fardet, L., Nazareth, I. & Petersen, I. Long-term systemic glucocorticoid therapy and weight gain: a population-based cohort study. Rheumatology\u00a060, 1502\u20131511 (2021).","journal-title":"Rheumatology"},{"key":"695_CR106","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.abd.2023.05.005","volume":"99","author":"LCP Tavares","year":"2024","unstructured":"Tavares, L. C. P., Caetano, L., de, V. N. & Ianhez, M. Side effects of chronic systemic glucocorticoid therapy: what dermatologists should know. An. Bras. Dermatol. 99, 259\u2013268 (2024).","journal-title":"An. Bras. Dermatol."},{"key":"695_CR107","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1136\/ard-2023-224460","volume":"82","author":"JM Mascaro","year":"2023","unstructured":"Mascaro, J. M. et al. Spanish cohort of VEXAS syndrome: clinical manifestations, outcome of treatments and novel evidences about UBA1 mosaicism. Ann. Rheum. Dis. 82, 1594\u20131605 (2023).","journal-title":"Ann. Rheum. Dis."},{"key":"695_CR108","doi-asserted-by":"publisher","first-page":"2231","DOI":"10.1182\/blood-2007-02-071423","volume":"110","author":"D Imanishi","year":"2007","unstructured":"Imanishi, D. et al. Donor-derived DNA in fingernails among recipients of allogeneic hematopoietic stem-cell transplants. Blood 110, 2231\u20132234 (2007).","journal-title":"Blood"},{"key":"695_CR109","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1080\/08880010601001362","volume":"24","author":"Z Ashena","year":"2007","unstructured":"Ashena, Z., Alavi, S., Arzanian, M. T. & Eshghi, P. Nail involvement in Langerhans cell histiocytosis. Pediatr. Hematol. Oncol. 24, 45\u201351 (2007).","journal-title":"Pediatr. Hematol. Oncol."},{"key":"695_CR110","doi-asserted-by":"publisher","first-page":"3269","DOI":"10.3324\/haematol.2024.285054","volume":"109","author":"M Krystel-Whittemore","year":"2024","unstructured":"Krystel-Whittemore, M. et al. Cell-free DNA from nail clippings as source of normal control for genomic studies in hematologic malignancies. Haematologica 109, 3269\u20133281 (2024).","journal-title":"Haematologica"},{"key":"695_CR111","doi-asserted-by":"publisher","first-page":"1997","DOI":"10.1038\/s41375-025-02671-x","volume":"39","author":"CA Clough","year":"2025","unstructured":"Clough, C. A. et al. Characterization of E1 enzyme dependencies in mutant-UBA1 human cells reveals UBA6 as a novel therapeutic target in VEXAS syndrome. Leukemia 39, 1997\u20132009 (2025).","journal-title":"Leukemia"},{"key":"695_CR112","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1038\/s41571-024-00966-z","volume":"22","author":"NYL Ngoi","year":"2024","unstructured":"Ngoi, N. Y. L. et al. Synthetic lethal strategies for the development of cancer therapeutics. Nat. Rev. Clin. Oncol. 22, 46\u201364 (2024).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"695_CR113","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/j.stem.2023.04.014","volume":"30","author":"S Ferrari","year":"2023","unstructured":"Ferrari, S. et al. Genetic engineering meets hematopoietic stem cell biology for next-generation gene therapy. Cell Stem Cell 30, 549\u2013570 (2023).","journal-title":"Cell Stem Cell"}],"container-title":["Nature Reviews Disease Primers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41572-026-00695-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41572-026-00695-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41572-026-00695-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T07:01:24Z","timestamp":1776322884000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41572-026-00695-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,16]]},"references-count":113,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["695"],"URL":"https:\/\/doi.org\/10.1038\/s41572-026-00695-w","relation":{},"ISSN":["2056-676X"],"issn-type":[{"value":"2056-676X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,16]]},"assertion":[{"value":"12 March 2026","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2026","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"D.B.B. is a consultant for GSK, Sobi, Novartis, Alexion and Genesis Therapeutics. S.G.-L. receives speaking and expertise fees from Novartis and Sobi. Y.K. receives speaking fees from Novartis, Amgen and consultation fees from Sobi, Novartis. S.F. is an inventor on a patent on methods and means of\n                      UBA1\n                      genetic modification for VEXAS syndrome (inventors: S.F., M. Fiumara, L. Naldini, R. Molteni, G. Cavalli; patent no. WO\/2025\/088508A1; status pending) jointly owned and managed by IRCCS San Raffaele Scientific Institute and Fondazione Telethon ETS. B.A.P. declares no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The authors affirm that human research participants provided informed consent for publication of the images in Fig.\u00a0\n                      \n                      .","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}],"article-number":"19"}}